| 2024-10-02 |
复牌提示：
2024-10-01 19:50:00 停牌，复牌日期 2024-10-03 00:00:01
|
| 2024-08-29 |
股东大会：
将于2024-09-27召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated July 19, 2024 (as it may be amended from time to time, the “Merger Agreement”), by and among Augmedix, Commure, Inc. (“Commure”), and Anderson Merger Sub, Inc. (“Merger Sub”), and approve the merger of Merger Sub with and into Augmedix (the “Merger”), with Augmedix continuing as the surviving corporation and a wholly owned direct subsidiary of Commure;
2.To consider and vote on a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement and approve the Merger at the time of the Special Meeting (the “Adjournment Proposal”);
3.To transact any other business that may properly come before the Special Meeting.
|
| 2024-08-29 |
详情>>
股本变动：
变动后总股本4942.81万股
|
| 2024-08-15 |
详情>>
内部人交易：
Krakaris Emmanuel等共交易12笔
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.28美元,归母净利润-1494.9万美元,同比去年增长-45.53%
|
| 2024-08-12 |
财报披露：
美东时间 2024-08-12 盘后发布财报
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.12美元,归母净利润-649.9万美元,同比去年增长-24.05%
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-0.44美元,归母净利润-1917.1万美元,同比去年增长21.59%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.35美元,归母净利润-1467.9万美元,同比去年增长22.13%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.25美元,归母净利润-1027.2万美元,同比去年增长23.25%
|
| 2023-06-26 |
股东大会：
将于2023-07-13召开股东大会
会议内容 ▼▲
- 1.To elect the three Class III director nominees named in the proxy statement to our board of directors;
2.To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, including shares issuable upon the exercise of warrants, pursuant to the Company’s Equity Line of Credit (as defined herein) (the “ELOC Issuance Proposal”);
3.To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the adjustment to the exercise price of the SVB Warrant (as defined herein) (the “Warrant Exercise Price Adjustment Proposal”);
4.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for 2023;
5.To transact such other business as may properly come before the Annual Meeting and any postponements or adjournments thereof.
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.14美元,归母净利润-523.9万美元,同比去年增长11.74%
|
| 2023-04-17 |
详情>>
业绩披露：
2022年年报每股收益-0.65美元,归母净利润-2444.9万美元,同比去年增长-40%
|
| 2022-11-18 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.5美元,归母净利润-1885万美元,同比去年增长-54.69%
|
| 2022-08-12 |
详情>>
业绩披露：
2022年中报每股收益-0.36美元,归母净利润-1338.3万美元,同比去年增长-40.27%
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益-0.16美元,归母净利润-593.6万美元,同比去年增长-21.04%
|
| 2022-05-02 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect the two Class II director nominees named in the proxy statement to our board of directors;
2.To ratify the appointment of Frank, Rimerman + Co. LLP as the Company’s independent registered public accounting firm for 2022;
3.To transact such other business as may properly come before the Annual Meeting and any postponements or adjournments thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|